Latest Insider Transactions at Voyager Therapeutics, Inc. (VYGR)
This section provides a real-time view of insider transactions for Voyager Therapeutics, Inc. (VYGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Voyager Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Voyager Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Julie Burek VP, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
3,063
+5.82%
|
$6,126
$2.3 P/Share
|
|
Nov 26
2021
|
Julie Burek VP, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+22.49%
|
-
|
|
May 21
2021
|
Omar Khwaja Officer |
SELL
Open market or private sale
|
Direct |
3,516
-2.83%
|
$14,064
$4.03 P/Share
|
|
Apr 05
2021
|
Robert W. Hesslein Senior VP & General Counsel |
BUY
Open market or private sale
|
Direct |
3,292
+2.9%
|
$13,168
$4.95 P/Share
|
|
Mar 19
2021
|
Allison Dorval Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+21.44%
|
-
|
|
Mar 19
2021
|
Andre Turenne President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.88%
|
-
|
|
Mar 19
2021
|
Robert W. Hesslein Senior VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.93%
|
-
|
|
Mar 19
2021
|
Omar Khwaja Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+22.01%
|
-
|
|
Feb 16
2021
|
Allison Dorval Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+29.85%
|
-
|
|
Feb 16
2021
|
Robert W. Hesslein Senior VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+28.97%
|
-
|
|
Feb 16
2021
|
Omar Khwaja Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+28.79%
|
-
|
|
Feb 16
2021
|
Andre Turenne President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,000
+27.95%
|
-
|
|
Feb 11
2021
|
Omar Khwaja Officer |
SELL
Open market or private sale
|
Direct |
3,475
-6.15%
|
$24,325
$7.55 P/Share
|
|
Feb 11
2021
|
Robert W. Hesslein Senior VP & General Counsel |
SELL
Open market or private sale
|
Direct |
3,186
-6.06%
|
$22,302
$7.55 P/Share
|
|
Feb 11
2021
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,186
-6.49%
|
$22,302
$7.55 P/Share
|
|
Feb 11
2021
|
Andre Turenne President & CEO |
SELL
Open market or private sale
|
Direct |
7,977
-5.1%
|
$55,839
$7.55 P/Share
|
|
Jan 12
2021
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,942
-5.66%
|
$23,536
$8.62 P/Share
|
|
Jan 12
2021
|
Andre Turenne President & CEO |
SELL
Open market or private sale
|
Direct |
10,443
-6.26%
|
$83,544
$8.62 P/Share
|
|
Sep 19
2018
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,500,000
-19.01%
|
-
|
|
Jun 20
2018
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,500,000
-15.97%
|
-
|
|
Nov 16
2015
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
125,000
+4.8%
|
$1,750,000
$14.0 P/Share
|
|
Nov 10
2015
|
Sanofi |
BUY
Conversion of derivative security
|
Indirect |
2,352,941
+50.0%
|
-
|